Open AccessThe journey of canakinumab; on- and off-label indications
Author(s) -
Daniela Marotto,
Alberto Batticciotto,
Angela Ceribelli,
Piercarlo SarziPuttini
Publication year - 2019
Publication title -
beyond rheumatology
Language(s) - English
Resource type - Journals
ISSN - 2612-5110
DOI - 10.4081/br.2019.4
Subject(s) - canakinumab , anakinra , medicine , disease
The role of interleukin-1 (IL-1) has been studied in many diseases, ranging from auto-inflammatory diseases to malignancies, and much has been discovered. There are currently four IL-1 inhibitors available, but only two have been approved in Europe: the receptor antagonist anakinra, and the IL-1b selective inhibitor canakinumab. The aim of this paper is to summarise the on- and off-label use of canakinumab (ILARIS®).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom